Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_assertion description "[The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP458846.RAdojwkELglgVPk5MED7l80m3QaugRm6Yju30bkaHMO5U130_provenance.
• assertion description "[The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP389498.RACKp-fAvVMq4V-oulXWN3OvoF_DY5qqI_vB3c5HpiEd8130_assertion description "[The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP389498.RACKp-fAvVMq4V-oulXWN3OvoF_DY5qqI_vB3c5HpiEd8130_provenance.
• NP335314.RARgiaEOninb97poSK4DgB-nNcrSO8zeYV7jWskPIftIw130_assertion description "[The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP335314.RARgiaEOninb97poSK4DgB-nNcrSO8zeYV7jWskPIftIw130_provenance.